- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
REGN34
SAO
Week ended 31 Jul 2026
Weekly Investor Report
Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
Latest close
64.27 BRL
15.4%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 4.8% above the Trend Line and sits at 63.0% of its 52-week range. The latest completed week returned 15.4%, after a 13.6% four-week move. The latest news-sentiment score is 44/100. Near-term considerations: volume confirmation is below normal.
Setup score
49
out of 100
Latest Close
64.27 BRL
31 Jul 2026
1W Return
15.4%
latest completed week
4W Return
13.6%
short-term follow-through
12W Return
8.4%
quarterly tape
Trend Breadth
46.2%
24 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
15.4%
Latest completed week; four-week move 13.6%.
Indicator stack
25/60
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
44/100
20 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 4.8% above the Trend Line and sits at 63.0% of its 52-week range. The latest completed week returned 15.4%, after a 13.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0612-week average 0.10
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure1/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.06Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 13.6% over four weeks, 8.4% over 12 weeks, and 27.8% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year24
Trend breadth46.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.09Latest activity-pressure read.
Pressure change107.8%Four-week change in activity pressure.
Leadership-0.14Latest relative-leadership reading.
RS change98.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment44/100
Weighted news tone is neutral across 20 relevant articles.
1 positive · 15 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-12.2%Distance below the 52-week high.
13-week volatility6.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher11 of 2615 weeks finished lower.
Best week+15.4%Week of 31 Jul.
Worst week-10.2%Week of 22 May.
Latest week+15.4%Week of 31 Jul.
Shape of recent returns
Strong gains4
Modest gains7
Flat weeks0
Modest losses10
Sharp losses5
Recent vol6.0%13-week weekly-return volatility.
Base vol5.3%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew4.8% / -3.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorBR Healthcare
4-week rank4 / 81
Group average-2.9%
Trend breadth30.9%
Trend30.9%active weekly trend signals
MD65.4%positive activity pressure
RS37.0%positive relative leadership
Four-week leaders
IndustryBR Biotechnology
4-week rank1 / 13
Group average-10.1%
Trend breadth30.8%
Trend30.8%active weekly trend signals
MD69.2%positive activity pressure
RS23.1%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape43/100
Trend, activity pressure, participation, and risk combine to a 43/100 tape read.
Indicator analysis11/100Latest 12-week confirmation: trend 0/12, activity pressure 1/12, relative leadership 0/12.
Activity pressure 0.06; No reversal markers Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment44/100Weighted news tone is neutral across 20 relevant articles.
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 64.27 BRL | 15.4% | 61.35 BRL | 69.43 BRL | 0.09 | -0.14 | 3.3K | Off |
| 24 Jul 2026 | 55.69 BRL | -4.1% | 61.52 BRL | 69.42 BRL | -0.28 | -11.59 | 1.0K | Off |
| 17 Jul 2026 | 58.08 BRL | 2.7% | 62.07 BRL | 69.43 BRL | -0.52 | -7.97 | 1.1K | Off |
| 10 Jul 2026 | 56.58 BRL | -0.0% | 62.48 BRL | 69.43 BRL | -0.88 | -12.64 | 3.4K | Off |
| 3 Jul 2026 | 56.60 BRL | 3.7% | 62.80 BRL | 69.43 BRL | -1.15 | -11.10 | 1.9K | Off |
| 26 Jun 2026 | 54.60 BRL | 5.2% | 63.08 BRL | 69.43 BRL | -1.38 | -13.88 | 1.7K | Off |
| 19 Jun 2026 | 51.90 BRL | -0.2% | 63.57 BRL | 69.44 BRL | -1.48 | -15.99 | 47 | Off |
| 12 Jun 2026 | 51.99 BRL | -4.8% | 64.09 BRL | 69.51 BRL | -1.41 | -17.25 | 206 | Off |
| 5 Jun 2026 | 54.63 BRL | 5.5% | 64.25 BRL | 69.57 BRL | -1.38 | -12.18 | 422 | Off |
| 29 May 2026 | 51.79 BRL | -2.9% | 64.35 BRL | 69.61 BRL | -1.36 | -19.08 | 5.5K | Off |
| 22 May 2026 | 53.31 BRL | -10.2% | 64.57 BRL | 69.67 BRL | -1.33 | -18.05 | 25.4K | Off |
| 15 May 2026 | 59.40 BRL | 0.1% | 64.50 BRL | 69.71 BRL | -1.20 | -9.70 | 2.4K | Off |
| 8 May 2026 | 59.32 BRL | 1.9% | 64.25 BRL | 69.73 BRL | -1.18 | -13.43 | 497 | Off |
| 1 May 2026 | 58.19 BRL | -6.8% | 64.00 BRL | 69.74 BRL | -1.09 | -16.72 | 3.3K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.